LeMaitre Vascular Reports 42% EPS Growth in Q1, Raises Full-Year Guidance
LMAT sits 44% above its 52-week low of $78.01.
Summary
LeMaitre Vascular reported exceptionally strong Q1 2026 financial results, with sales increasing 11% and diluted EPS surging 42% year-over-year to $0.68. The company also significantly raised its full-year 2026 guidance, now projecting 12% sales growth and 26% adjusted EPS growth, reflecting strong operational leverage. This robust performance was driven by record sales across key product lines like Artegraft (+36%) and all three geographies. The positive results and increased outlook are highly material, indicating strong business momentum and improved profitability, which should be viewed favorably by investors. While the company also announced a routine quarterly dividend and reiterated its existing share repurchase program, the core earnings beat and raised guidance are the primary drivers for immediate trader attention. Investors will now focus on the company's ability to maintain this accelerated growth and margin expansion.
At the time of this announcement, LMAT was trading at $112.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $78.01 to $118.01. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.